The Aescap funds have focused portfolios of around 20 companies each, to enable an out-performance of our bench mark, the Nasdaq Biotech Index (NBI). Investment decisions are based on thorough research, fundamental analyses and advanced company valuations based on the calculation of the net present value (NPV). In the biotech sector, such an analysis especially encompasses the product portfolio, patent protection, product development risks, market entry barriers, competition and the expected market development. But perhaps even more vital to our process are the serious efforts we undertake to understand the strengths and weaknesses of a company’s management, track record, team dynamics, and their view on the future of the company and the markets they serve.
We believe companies can truly make a difference if their products differentiate themselves from their competitors. We, therefore, actively search for companies that develop next-generation medicines based on well patented ground-breaking technologies. We are most interested in medicine that treat diseases with a high unmet medical need and medicine that lower the overall cost of care.